Cite
HARVARD Citation
Cicerone, C. et al. (n.d.). P.07.36 REAL-WORLD EVIDENCE OF VEDOLIZUMAB THERAPY IN ULCERATIVE COLITIS AND CROHN'S DISEASE PATIENTS: FECAL CALPROTECTIN A VALID BIOMARKER OF MUCOSAL INFLAMMATION. Digestive and liver disease. pp. e239-. [Online].